In this regard, our results correspond well to previous reports that SST-based positron emission tomography (PET) or PET/computed tomography is suitable in only a selected group of thyroid cancer patients [52–57], that somatostatin analogues like octreotide show no beneficial effect in the treatment of thyroid carcinomas [52, 58], and that a very limited number of patients benefits from SST-based peptide receptor radionuclide therapy [23, 52–55]. The gene discussed is SST; the disease is thyroid gland carcinoma.